Findit enters definitive merger with BioRegenx; existing shareholders to hold 10% of voting stock

BIOREGENX, INC.

BioRegenx shareholders will receive common and preferred shares equivalent to 90% of Findit's voting securities.
Findit Series A and B preferred shares (98.47% voting control) will be retired into treasury.
Both parties agree to implement up to a 1-for-25 reverse stock split post-merger.
Merger expected to close in Q1 2023, subject to shareholder and regulatory approvals.
Combined entity will be renamed BioRegenx, Inc. and apply for a new ticker symbol.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BIOREGENX, INC. entered into Merger Agreement with BioRegenx, Inc. (effective 2022-12-29).

Action: entry
Agreement: merger
Counterparty: BioRegenx, Inc.
Effective: 2022-12-29

Exact text from the filing

On December 29, 2022, Findit, Inc. (the “Company” or “Findit”) announced it had entered into a definitive merger agreement (the “Merger Agreement”) with BioRegenx, Inc. (“BioRegenx”), a Nevada corporation.

View on SEC.gov

Browse all material agreements →

BIOREGENX, INC. filing history →

Source: SEC EDGAR

accession 0001800943-23-000001

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.